Trials coming soon

Prostate Cancer: EVOLUTION (ANZUP 2001)

A Phase II Trial of dual

EVOLUTION PRINCIPAL Immunotherapy and Lu-PSMA

INVESTIGATOR, ASSOCIATE in metastatic castration resistant

PROFESSOR prostate cancer (mCRPC)

SHAHNEEN SANDHU Although men with metastatic prostate cancer initially respond to hormone treatments, many will develop castration-resistant prostate cancer, i.e., their cancer continues to grow despite hormone treatment. This condition is called mCRPC. Immunotherapy and Lutetium-177 PSMA (Lu-PSMA for short) are two treatments that we hope might help men in this situation.

Prostate Cancer: DIPPER (ANZUP 2002)

A multi-centre, randomised phase DIPPER PRINCIPAL 2 clinical trial of early salvage INVESTIGATOR, DR MATT ROBERTS radiotherapy versus surveillance for biochemical recurrence after radical prostatectomy incorporating clinical and imagingbased risk stratification.

Ipilimumab and nivolumab are immunotherapy drugs that activate the body’s own immune response to kill cancer cells. Both ipilimumab and nivolumab allow the immune system to “see” the cancer, seek it out and destroy it. These treatments are given intraveneously (IV) and have been effective in treating other cancers like melanoma, kidney and lung cancers, but studies of ipilimumab and nivolumab in men with prostate cancer remain experimental at present.

Lu-PSMA is a type of treatment called radionuclide therapy that can be used to treat prostate cancer by bringing radioactive atoms into the cancer cells. Many prostate cancers, in particular those that have spread or become resistant to hormonal therapies, have a substance on their cell surface called prostate specific membrane antigen (PSMA). Lu-PSMA attaches to PSMA on the surface of prostate cancer cells and delivers radiation to the cancer cell, without much radiation exposure to other parts of the body. Recent studies have shown that Lu-PSMA is a promising treatment for men with metastatic prostate cancer that is no longer under control after several standard treatments.

CYCLE, RUN OR WALK TO RAISE AWARE OR BELOW THE BELT CANCER RESEARCH nnounce our new campaign – Below the Belt #YourWay and invit ourWay or run #YourWay as many km’s as you can. ou can do it at home, at the office, or in the great outdoors. What eeded funds for below the belt cancer research. Keeping both your h work colleagues, with a friend or alone. Do it every day or Open to all in Australia and New Zealand. elp raise $100,000 for below the belt (bladde The aim of this study is to see if combining ipilimumab r, kidney, penile, p and nivolumab with Lu-PSMA can further improve the anti-cancer effects of Lu-PSMA. It is thought that or our Pedalthoners, we encourage you to sign up to this fantastipilimumab and nivolumab and Lu-PSMA may work ic new campaign as we will be post low the Belt Pedalthon in Sydney until 2021. C Cycle #Yotogether to treat the cancer. Lu-PSMA can potentially urWay instead. ss and help fund future clinical trials for below the belt cancers. kill cancer cells and break up the tumour into small pieces that may be recognised by your immune system IF YOU ARE INTERESTED IN FINDING OUT MORE while ipilimumab and nivolumab helps your immune system to be activated to find and attack your cancer. REGISTER YOUR INTEREST HERE. This new treatment combination may lead to shrinkage or stabilisation of previously progressing tumours and therefore hopefully stop or reverse the growth of your cancer. We plan to enrol 100 Australian men in this trial. Fight Cancer Below the Belt, #YourWay

Current best standard treatment for prostate cancer following radical prostatectomy is uncertain. Previous studies using traditional imaging methods, including computed tomography (CT) and bone scan, showed that radiation therapy was the best way to control PSA levels and return of cancer where the prostate was previously located (local recurrence). Whether radiation therapy reduced the spread of cancer around the body (metastases) or prolonged life (overall survival) was not conclusively proven. Use of radiation therapy also can result in significantly unpleasant side effects, which can affect quality of life. Conversely, personalised selection of men for surveillance using pathology, blood and imaging tests may identify a group of men who can forego additional treatments for the same cancer outcome and avoid side effects. Currently in Australia, with widespread adoption of PSMA PET scanning, unfortunately clinicians cannot agree on the best approach. The main aim of the study is to see if using radiation therapy to the prostate bed and/or close lymph glands is better than active surveillance for cancer control in a carefully selected group of men with low-risk features and negative PSMA PET imaging. The study also aims to determine: i. the effect of study treatment on other measures of how well the prostate cancer is controlled, ii. the effects of treatment on quality of life, iii. differences in the costs of care for people on treatment, iv. tests that might identify people who are more or less likely to benefit from treatment, and v. practice patterns among clinicians in participating hospitals. Recent studies show that radiation therapy leads to good cancer control rates, but almost half of men will have acceptable control with no treatment. This phenomenon was shown in Australian and international clinical trials comparing this approach immediately after surgery (adjuvant versus early salvage radiation therapy), where similar cancer control was observed overall but >60% of men avoided radiation therapy. This is the first randomised clinical trial evaluating the potential benefit of personalised patient selection and different treatments for your type of prostate cancer. We plan to enrol almost 200 participants in the study in Australia.